US20020006432A1 - Bifidobacterium in the treatment of inflammatory disease - Google Patents

Bifidobacterium in the treatment of inflammatory disease Download PDF

Info

Publication number
US20020006432A1
US20020006432A1 US09/903,681 US90368101A US2002006432A1 US 20020006432 A1 US20020006432 A1 US 20020006432A1 US 90368101 A US90368101 A US 90368101A US 2002006432 A1 US2002006432 A1 US 2002006432A1
Authority
US
United States
Prior art keywords
strain
bifidobacterium
formulation
cells
lactobacillus salivarius
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/903,681
Other languages
English (en)
Inventor
John Collins
Gerald O'Sullivan
Liam O'Mahony
Fergus Shanahan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cork
Enterprise Ireland
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IE990033A external-priority patent/IE990033A1/en
Application filed by Individual filed Critical Individual
Assigned to ENTERPRISE IRELAND (TRADING AS BIORESEARCH IRELAND) GLASNEVIN, NATIONAL UNIVERSITY OF IRELAND, CORK reassignment ENTERPRISE IRELAND (TRADING AS BIORESEARCH IRELAND) GLASNEVIN ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COLLINS, JOHN KEVIN, O'MAHONEY, LIAM, O'SULLIVAN, GERALD CHRISTOPHER, SHANAHAN, FERGUS
Publication of US20020006432A1 publication Critical patent/US20020006432A1/en
Priority to US10/376,602 priority Critical patent/US20030170217A1/en
Priority to US10/388,652 priority patent/US20030215467A1/en
Priority to US10/783,020 priority patent/US7195906B2/en
Priority to US10/956,330 priority patent/US20050214272A1/en
Priority to US10/975,353 priority patent/US20060002908A1/en
Priority to US11/478,545 priority patent/US20070141039A1/en
Priority to US11/699,115 priority patent/US20080057109A1/en
Priority to US12/123,052 priority patent/US20080311080A1/en
Priority to US12/479,364 priority patent/US20100112003A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/179—Sakei
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus

Definitions

  • This invention relates to probiotic Bifidobacterium strains which have various applications in foodstuffs and in medicine. More particularly, the invention relates to probiotic strains of bifidobacteria which are capable of beneficially modifying and consequently alleviating observable symptoms in inflammatory disease.
  • GIT gastrointestinal tract
  • IBS irritable bowel syndrome
  • EBD inflammatory bowel disease
  • Probiotics have been defined as live microbial food supplements which beneficially affect the host by improving the intestinal microbial balance, or more broadly, as living micro-organisms, which upon ingestion in certain numbers, exert health effects beyond inherent basic nutrition.
  • Criteria which have been suggested for the selection of potentially effective probiotic micro-organisms may be summarised as follows: human origin, non-pathogenic behaviour, resistance to technological processes (i.e., viability and activity in delivery vehicles), resistance to gastric acidity and bile toxicity, adhesion to gut epithelial tissue, ability to colonise the GIT, production of antimicrobial substances, ability to modulate immune responses, and the ability to influence metabolic activities (e.g., cholesterol assimilation, lactase activity, vitamin production) (Huis in't Veld J, Shortt C. Selection criteria for probiotic micro-organisms. In: Leeds, A. R., Rowland, I. R. eds. Gut Fora and Health—Past, Present and Future. London: The Royal Society of Medicine Press Ltd., 1996:19-26).
  • Bifidobacteria are one of several predominant culturable bacteria present in the colonic microflora.
  • Bifidobacteria are considered to be probiotics as they are living organisms which exert healthy effects beyond basic nutrition when ingested in sufficient numbers. Numerous ingested bifidobacteria must reach the site of action in the gut in order to exert a probiotic effect. A minimum level of approximately 10 6 -10 7 viable bifidobacteria per gram intestinal contents has been suggested (Bouhnik, Y., Lait 1993: 73:241-247). There are reports in the literature which show that in vivo studies completed in adults and in infants indicate that some strains of bifidobacteria are capable of surviving passage through the gastrointestinal tract. Significant differences have been observed between the abilities of different bifidobacteria strains to tolerate acid and bile salts, indicating that survival is an important criterion for the selection of potential probiotic strains.
  • Antimicrobial activity has been reported to be associated with bifidobacteria. Also, bifidobacteria have been shown to modulate various parameters of the immune system.
  • the invention provides a strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract which is significantly immunomodulatory following oral consumption in humans.
  • the strain of Bifidobacterium preferably effects changes in an immunological marker when introduced into a system comprising cells which interact with the immune system and cells of the immune system.
  • the cells which interact with the immune system are epithelial cells.
  • the immunological marker is a cytokine, especially TNF ⁇ .
  • the cells which interact with the immune system and the immune system cells are of matched origin.
  • the cells which interact with the immune system are of gastrointestinal, respiratory or genitourinary origin.
  • the cells of the immune system are preferably of gastrointestinal, respiratory or genitourinary origin.
  • the invention also provides a strain of Bifidobacterium longum infantis isolated from resected and washed human gastrointestinal tract which is significantly immunomodulatory following oral consumption in humans.
  • the strain of Bifidobacterium is preferably isolated from resected and washed human gastrointestinal tract which is capable of combating the effects of inflammatory bowel disease, said capability being maintained in the presence of physiological concentrations of human bile and human gastric juice.
  • the capability of combating the effects of inflammatory bowel disease is measured by measuring a reversal of a wasting disease induced in severe combined immunodeficient recipient mice (SCID) which have been administered purified CD4 + , CD45RB high T cells.
  • SCID severe combined immunodeficient recipient mice
  • the capability of the strain of Bifidobacterium longum infantis to combat the effects of inflammatory bowel disease can also be measured by measuring the reduction in colonic inflammation in IL-10 deficient mice (IL-10 + 129 Svex strain) following administration of one or more of the strains of Bifidobacterium longum infantis according to the invention alone or in combination with a strain of Lactobacillus salivarius as hereinafter defined.
  • Interleukin 10 is an important regulatory cytokine that supresses effector functions of macrophage/monocytes, T helper 1 (Th1) cells, and natural killer cells.
  • Th1 T helper 1
  • IL-10 augments proliferation and differentiation of B cells.
  • Murine models lacking the IL-10 gene spontaneously develop inflammatory bowel disease and gastrointestinal tumors. The gastrointestinal flora have been implicated in the pathogenesis of these disease states as germ free animals do not develop disease.
  • the strain of Bifidobacterium preferably has inhibitory activity against a broad range of Gram positive and Gram negative bacteria.
  • the strain of Bifidobacterium exhibits a broad-spectrum of activity against bacteria including Staphylococcus, Pseudomonas, Coliform and Bacilus species.
  • the invention provides strain of Bifidobacterium longum infantis UCC35624 or mutant or variant thereof.
  • a deposit of Bifidobacterium longum infantis strain UCC 35624 was made at the National Collections of Industrial and Marine Bacteria Limited (NCIMB) on Jan. 13, 1999 and accorded the accession number NCIMB 41003.
  • the mutant is a genetically modified mutant.
  • the variant is a naturally occurring variant of Bifidobacterium longum infantis UCC35624.
  • the strain of Bifidobacterium may be in the form of viable cells.
  • the strain of Bifidobacterium is in the form of non-viable cells.
  • the invention also provides an antimicrobial agent obtained from a strain of Bifidobacterium of the invention which is antagonistic to the growth of other organisms.
  • the invention provides a formulation which comprises a strain of Bifidobacterium of the invention.
  • the formulation may comprise two or more strains of Bifidobacterium.
  • the formulation may include another probiotic material.
  • the formulation includes a prebiotic material.
  • the formulation may which include a strain of Lactobacillus salivarius.
  • the strain of Lactobacillus salivarius may be in the form of viable cells or in the form of non-viable cells.
  • the Lactobacillus salivarius is preferably isolated from resected and washed human gastrointestinal tract, the Lactobacillus salivarius being significantly immunomodulatory following oral consumption in humans.
  • the strain of Lactobacillus salivarius is isolated from resected and washed human gastrointestinal tract which inhibits a broad range of Gram positive and Gram negative micro-organisms.
  • the strain of Lactobacillus salivarius secretes a product having antimicrobial activity into a cell—free supernatant, said activity being produced only by growing cells and being destroyed by proteinase K and pronase E, the inhibitory properties of said strain and its secretory products being maintained in the presence of physiological concentration of human bile and human gastric juice.
  • the strain of Lactobacillus salivarius is Lactobacillus salivarius strain UCC 118 or a mutant or variant thereof.
  • the mutant is a genetically modified mutant.
  • the variant may be a naturally occurring variant of Lactobacillus salivarius.
  • Lactobacillus salivarius strain UCC 118 was made at the NCIMB on Nov. 27, 1996 and accorded the accession number NCIMB 40829.
  • the formulation includes an ingestable carrier.
  • the ingestable carrier may be a pharmaceutically acceptable carrier such as a capsule, tablet or powder.
  • the ingestable carrier may be a food product such as acidified milk, yoghurt, frozen yoghurt, milk powder, milk concentrate, cheese spreads, dressings or beverages.
  • the formulation may comprise a protein and/or peptide, in particular proteins and/or peptides that are rich in glutamine/glutamate, a lipid, a carbohydrate, a vitamin, mineral and/or trace element.
  • the Bifidobacterium is present at more than 10 6 cfu per gram of delivery system.
  • the formulation includes an adjuvant.
  • the formulation may include a bacterial component.
  • the formulation may alternatively or additionally include a drug entity.
  • the formulation may also include a biological compound.
  • the formulation may be in a form for oral immunisation.
  • the invention further provides a strain of Bifidobacterium or a formulation thereof for use in foodstuffs.
  • the invention provides a strain of Bifidobacterium or a formulation thereof for use as a medicament.
  • the strain or formulation may be for use in the prophylaxis and/or treatment of undesirable inflammatory activity.
  • the strain or formulation may be for use in the prophylaxis and/or treatment of undesirable gastrointestinal inflammatory activity such as inflammatory bowel disease eg. Crohns disease or ulcerative colitis, irritable bowel syndrome, pouchitis or post infection colitis.
  • undesirable gastrointestinal inflammatory activity such as inflammatory bowel disease eg. Crohns disease or ulcerative colitis, irritable bowel syndrome, pouchitis or post infection colitis.
  • the undesirable inflammatory activity may be due to cancer.
  • strain or formulation may be for use in the prophylaxis and/or treatment of gastrointestinal cancer(s).
  • the strain or formulation may be used for the prophylaxis of cancer. Further, the strain or formulation may be for use in the prophylaxis and/or treatment of systemic disease such as rheumatoid arthritis.
  • the strain or formulation may be for use in the prophylaxis and/or treatment of autoimmune disorders due to undesirable inflammatory activity.
  • the strain or formulation may be for use in the prophylaxis and/or treatment of cancer due to undesirable inflammatory activity.
  • the strain or formulation may be for use in the prophylaxis and/or treatment of diarrhoeal disease due undesirable inflammatory activity, such as Clostridium difficile associated diarrhoea, Rotavirus associated diarrhoea or post infective diarrhoea.
  • FIG. 1 is a graph of cfu/ml versus time for Bifidobacterium longum infantis strain 35612 as described in Example 2;
  • FIG. 2 is a graph of cfu/ml versus time for Bifidobacterium longum infantis strain 35624 as described in Example 2;
  • FIG. 3 is a graph of percentage weight change versus time (days) for five SCID mice (1-5) administered strain UCC 35624 as described in Example 5;
  • FIG. 4 is a graph of average percentage weight change versus time (days) for the SCID mice (1-5) administered stain UCC 35624 as described in Example 5;
  • FIG. 5 is a graph of percentage weight change versus time (days) for mice (6-10) administered a combination of strains Lactobacillus salivarius UCC 118 and UCC 35624 as described in Example 5;
  • FIG. 6 is a graph of average percentage weight change versus time (days) for mice (6-10) administered a combination of strains UCC 118 and UCC 35624 as described in Example 5;
  • FIG. 7 is a graph of percentage weight change versus time (days) for mice (11-15) administered a combination of strains UCC 118 and UCC 35624 as described in Example 5;
  • FIG. 8 is a graph of average percentage weight change versus time (days) for mice (11-15) administered a combination of strains UCC 118 and UCC 35624 as described in Example 5;
  • FIG. 9 is a bar chart of TNF ⁇ levels in patient and control samples in the presence of PBMCs and Bifidobacterium longum infantis as described in Example 7;
  • FIG. 10 is a bar chart showing TNF ⁇ and IL-8 levels in co-cultures of epithelial cells, PBMCs and Bifidobacterium longum infantis as described in Example 7. Controls represent co-cultures of epithelial cells and PBMCs alone;
  • FIG. 13 is a bar chart of TNF ⁇ levels in cell-free spent culture supernatant of Bifidobacterium longum infantis and an MRS control as described in Example 9;
  • FIG. 14 is a diagrammatic representation of a SCID mouse lower intestine after treatment with Bifidobacterium longum infantis.
  • FIG. 15 is a diagrammatic representation of the lower intestine of an untreated SCID mouse.
  • strains of probiotic bacteria which are capable of beneficially modifying and consequently alleviating observable symptoms in inflammatory disorders.
  • These strains and the formulations prepared may be used in a variety of foodstuffs and medicaments to combat the effect of inflammatory disorders.
  • mice consuming Bifidobacterium longum infantis retained solid stools while control mice suffered from diarrhoea.
  • This anti-diarrhoeal effect could be related to the anti-inflammatory activity of this invention, possibly mediated via cAMP modulation.
  • LPS lipopolysaccharide
  • Bifidobacterium longum infantis UCC35624 is in the form of viable cells. However, it can also be extended to non-viable cells such as killed cultures or compositions containing beneficial factors expressed by Bifidobacterium longum infantis UCC35624. This could include thermally killed micro-organisms or micro-organisms killed by exposure to altered pH or subjection to pressure. With non-viable cells product preparation is simpler, cells may be incorporated easily into pharmaceuticals and storage requirements are much less limited than viable cells. Lactobacillus casei YIT 9018 offers an example of the effective use of heat killed cells as a method for the treatment and/or prevention of tumour growth as described in U.S. Pat. No. 4,347,240.
  • the solutions were serially diluted (dilution 10 ⁇ 1 from a wash sample was labelled W1, dilution 10-2 was labelled W2 and the same labelling system was used for the ‘S’ and ‘H’ samples) and spread-plated (100 ⁇ l) on to the following agar media: RCM (reinforced clostridial media) and RCM adjusted to pH 5.5 using acetic acid; TPY (trypticase, peptone and yeast extract), Chevalier, P. et al. (1990) J. Appl. Bacteriol 68, 619-624).
  • MRS deMann, Rogosa and Sharpe
  • ROG acetate medium (SL) of Rogosa
  • LLA Liver-lactose agar of Lapiere
  • BHI brain heart infusion agar
  • LBS Lactobacillus selective agar
  • TSAYE tryptone soya agar supplemented with 0.6% yeast extract. All agar media was supplied by Oxoid Chemicals with the exception of TPY agar. Plates were incubated in anaerobic jars (BBL, Oxoid) using CO 2 generating kits (Anaerocult A, Merck) for 2-5 days at 37° C.
  • Gram positive, catalase negative rod-shaped or bifurcated/pleomorphic bacteria isolates were streaked for purity on to complex non-selective media (TPY). Isolates were routinely cultivated in TPY medium unless otherwise stated at 37° C. under anaerobic conditions. Presumptive Bifidobacteria species were stocked in 40% glycerol and stored at ⁇ 20° and ⁇ 80° C.
  • Biochemical and physiological traits of the bacterial isolates were determined to aid identification. Nitrate reduction, indole formation and expression of ⁇ -galactosidase activity were assayed. Growth at both 15° C. and 45° C. and protease activity on gelatin were determined. Growth characteristics of the strains in litmus milk were also assessed.
  • Antibiotic sensitivity profiles of the isolates were determined using the ‘disc susceptibility’ assay. Cultures were grown up in the appropriate broth medium for 24-48 h, spread-plated (100 ⁇ l) onto agar media and discs containing known concentrations of the antibiotics were placed onto the agar. Strains were examined for antibiotic sensitivity after 1-2 days incubation at 37° C. under anaerobic conditions. Strains were considered sensitive if zones of inhibition of 1 mm or greater were seen.
  • tissue sections taken from the-human G.I.T. were screened for the presence of strains belonging to the Bifidobacterium genus. There was some variation between tissue samples as follows. Samples A (ileum) and E (appendix) had the lowest counts with approximately 10 2 cells isolated per gram of tissue. In comparison, greater than 10 3 cfu/g tissue were recovered from the other samples. Similar numbers of bacteria were isolated during the ‘wash’ and ‘sample’ steps with slightly higher counts in the ‘sample’ solutions of F (ileum) and G (ileal-caecal). Of those screened for tightly-adhering bacteria (homogenised), C (ileal-caecal) was the only tissue section that gave significant counts.
  • Antibiotics of human clinical importance were used to ascertain the sensitivity profiles of selected bifidobacteria.
  • the bifidobacteria tested were sensitive to ampicillin, amoxycillin ceftaxime, ceftriaxone, ciprofloxacin, cephradine, rifampicin, amikacin, gentamicin and chloramphenicol. They were also resistant to netilmicin, trimethoprim, nalidixic acid, cefuroxime, vancomycin and tetracycline.
  • the first line of host defence that a microorganism reaches following human consumption is gastric acid in the stomach.
  • a key factor influencing bacteria is survival in gastric juice.
  • the survival and growth of Bifidobacterium longum infantis strains 35612 and 35624 in a low pH environment were examined The strains were routinely cultured in trypticase-peptone-yeast extract (TPY) medium at 37° C. under strict anaerobic conditions (BBL Gas jars using the Merck Anaerocult A gas pak system) for 12-24 h.
  • TPY trypticase-peptone-yeast extract
  • BBL Gas jars using the Merck Anaerocult A gas pak system for 12-24 h.
  • Human gastric juice was obtained from healthy subjects by aspiration through a nasogastric tube (Mercy Hospital, Cork, Ireland).
  • Human bile was obtained from several human gall bladders and sterilised at 80° C. for 10 min.
  • the bile acid composition of human bile was determined using reverse phase High Performance Liquid Chromatography (HPLC) in combination with a pulsed amperometric detector according to the method of Delker, R. R. et al., Chromatographia, 1991, 31 (11/12), 255-256.Human bile was added at a concentration of 0.3% (v/v). Freshly streaked cultures were examined for growth after 24 and 48 h.
  • HPLC High Performance Liquid Chromatography
  • Strain 35624 was capable of growth in the presence of physiologically relevant human bile (0.3% (v/v)).
  • glycocholic acid (GCA); glycodeoxycholic acid (GDCA); and glycochenodeoxycholic acid (GCDCA);
  • Bifidobacterium species exert inhibitory effects on other bacteria by excluding long term colonisation by invasive pathogens. Their antagonistic activity is due to the production of acetic and lactic acid though fermentation (Scardovi, V. (1986) Bifidibacterium in Bergey's Manual of systemic bacteriology, Vol. 2. Eds. Sheath, P. H., Main, N. S., Sharpe, M. and Holdt, J. G., Williams and Wilkins Publishers, Baltimore Md., p1418). Very few reports exist on the production of antimicrobial compounds other than acids (Anand, S. K. et al. Cult. Dairy Prods. 1985; J. 2, 21-23). Bacteriocins and other compounds may influence the survival of a bacterium in an ecological niche and allow them to effectively dominate fermenting ecosystems. Such a feature is a good trait for a probiotic strain.
  • the inhibitory spectra of various bifidobacterial strains was determined by the method of Tagg et al. CTagg. J. R. et al. Bacteriol. Rev. 1976; 40, 722-756). Cell free supernatant was assayed for inhibitory activity against a wide range of Gram positive and Gram negative micro-organisms. Overlays of each indicator were prepared on agar plates and allowed to dry. Spots (5 ml) of cell free supernatant were placed on the seeded plates, allowed to dry and the plates were incubated overnight.
  • mice have recently been generated by either genetic or immunological means to study the mechanisms of IBD.
  • One of these models involves the transfer of spleen or lymph node-derived CD4 + T lymphocytes from normal mice into severe combined immunodeficient recipient mice (SCID). It has been demonstrated that mice who receive purified CD4 + , CD45RB high T cells develop a wasting disease characterised by chronic intestinal inflammation which is more severe in the colon.
  • SCID mice was injected with CD4 + CD45RB high and the mice developed a progressive wasting disease including hunched over appearance, piloerection of the coat, diarrhoea, weight loss and macro and microscopic colon damage.
  • a feeding trail was set up administering UCC 118 and strain 35624 (also referred to herein as UCC 35624) to determine if the symptoms of IBD could be modified in this model.
  • Lactobacilius salivarius subsp. Salivarius UCC 118 and Bifidobacterium longum infantis UCC 35624 were isolated from the ileal-caecal region of an adult human as described in Example 1.
  • spontaneous rifampicin and streptomycin resistant derivatives of the strains were generated by plating cells, previously grown overnight and subsequently washed in quarter strength Ringer's solution on MRS and TPY agar containing 50 ⁇ g/ml rifampicin (Sigma) respectively and MRS containing 400 ⁇ g/ml streptomycin (Sigma). Plates were incubated for 2 days at 37° C. anaerobically. The resulting antibiotic resistant derivatives were determined to be otherwise phenotypically similar to the parent strain. This selectable trait enabled the strains to be readily enumerated following gut transit.
  • Donor mice C57BL/6 ⁇ BALB/c F1 were purchased from Simosen Laboratories (Gilroy, CA) and maintained at the University of California—Los Angeles vivarium in ventilated cage racks (Thoren caging systems, Hazelton, Pa.) under specific pathogen free (SPF) conditions.
  • CB-17 SCID mice were bred in ventilated cage racks originally obtained from the University of California—Los Angeles SCID core facility. The mice were reduced flora (RF) mice rather than germ free and acting as the recipient mice (Aranda R. et al. J. of Immunol. 1997; 158(7), 3464-3473).
  • mice Eight week old, female CB-17 (SCID) mice were housed in pairs in filter top cages in ventilated racks. The mice were divided into four groups Group A: consumed 10% skim milk, control; Group B: consumed Lactobacillus salivarius UCC 118, Group C: consumed Lactobacillus salivarius UCC 118 and Bifidobacterium longum UCC 35624 9 (1:1 ratio); Group D: consumed Bifidobacterium longum UCC 35624.
  • Group A consumed 10% skim milk, control
  • Group B consumed Lactobacillus salivarius UCC 118
  • Group C consumed Lactobacillus salivarius UCC 118 and Bifidobacterium longum UCC 35624 9 (1:1 ratio)
  • Group D consumed Bifidobacterium longum UCC 35624.
  • UCC 118 and UCC 35624 which were grown overnight in MRS broth and MRS broth supplemented with 0.05% cysteine (Sigma) respectively, were washed in PBS, resuspended in skim milk (10% (v/v)) and administered in the otherwise sterile drinking water (PBS).
  • the mice in each respective group received 2.55 ⁇ 10 8 cfu/ml of UCC 118 and 2.35 ⁇ 10 8 cfu/ml of UCC 35624 daily for the duration of the feeding period.
  • Control mice received sterile milk diluted in sterile phosphate buffered saline (PBS) and were maintained under identical conditions as the test group.
  • PBS sterile phosphate buffered saline
  • mice were administered their respective feed according to their grouping for 2 days prior to injection with the CD4 + CD45RB high cells.
  • the sorted donor lymphocytes (3-4 ⁇ 10 5 ) were represented in 200 ⁇ l of sterile PBS and injected i.p. into the recipient CB-17 SCID mice. All mice were weighed initially, then twice weekly thereafter. They were observed for clinical signs of illness: hunched over appearance, piloerection of the coat and diarrhoea.
  • the selective media used were; de Mann Rogosa & Sharpe (MRS) agar; MRS agar supplemented with 0.2% lithium chloride (BDH), 0.3% sodium propionate (Fluke chemie), 0.5% cysteine hydrochloride (Sigma), and 5% sheep's blood; Slanetz and Bartley agar; Wilkins and Chalgren agar supplemented with anaerobic supplement SR 108 and 5% horse blood; and Violet Red Bile Agar. (All Oxoid unless otherwise stated).
  • VRBA and Slanetz and Bartley plates were incubated aerobically for 24 and 45 h respectively. All other plates were incubated anaerobically for 48 h at 37° C.
  • mice were sacrificed and dissected. Segments of the ileal-caecal region, small intestine, and the large intestine were removed. A peripheral lymph node (PLN), mesenteric lymph node (MLN) and a piece of the spleen were also taken. All tissues were weighed before being resuspended in 10 ml of PBS. Samples were then homogenised and serially diluted in PBS and either spread plated or pour plated in appropriate dilutions on appropriate media in duplicate. The bacterial groups were enumerated the same as. those enumerated in the faecal analysis and samples were incubated as described previously.
  • PPN peripheral lymph node
  • MN mesenteric lymph node
  • Tissue samples were taken from the small intestine, large intestine, and ileal caecal region and fixed in 10% formalin. The procedure was as described in Aranda, R. et al. ((1997) supra).
  • mice reconstituted with CD4 + CD45RB high T lymphocytes and consuming skim milk alone developed a progressive wasting disease, identified by their significant weight loss. Disease became apparent at about 2 and a half to three weeks and the sick mice characteristically manifested a hunched over appearance, piloerection of their coat, and loose stool.
  • mice in the control group died after 25 days and mice 1, 2, 3 and 5 showed a ⁇ 20%, 25%, 21% and ⁇ 35% percentage weight change respectively as depicted in FIGS. 3 and 4.
  • Table 8 is a summary of experimental data for the study on the treatment of CD45RB colitis induced CB17 and SCID mice with a cocktail of UCC 118 and UCC 35624.
  • mice were successfully reconstituted with lymphocytes and lymphocytes having been derived from the donor model (data not shown).
  • TABLE 8 Treatment of CD45RB colitis induced CB 17 SCID mice with a cocktail of Lactobacillus salivarius UCC 118 and Bifidobacteria.
  • Bifidobacterium longum infantis (1 ⁇ 10 9 cells per day) was consumed by 18 healthy humans in a fermented milk yoghurt) product for three weeks. Serum was collected for cytokine analysis pre and post consumption of this probiotic strain. Faecal samples were obtained for microbiological analysis.
  • Targeted in vitro selection criteria reflecting the complex interactions of the GI environment allow for the identification of probiotic strains capable of functioning effectively when reintroduced into that environment Using the selection criteria outlined above, the probiotic bacteria Bifidobacterium longum infantis has demonstrable immunomodulating properties in vitro. Following consumption by SCID mice and human volunteers, significant modification of systemic immune parameters was noted. Thus, the use of Bifidobacterium longum infantis as a biotherapeutic agent in the treatment of immune mediated diseases is warranted.
  • Bifidobacterium longum infantis UCC35624 secretes a factor that antagonises TNF ⁇ activity. Production of this factor by Bifidobacterium longum infantis at the surface of the gastrointestinal tract, in vivo, would significantly restrict the host inflammatory response.
  • Inflammation is the term used to describe the local accumulation of fluid, plasma proteins and white blood cells at a site that has sustained physical damage, infection or where there is an ongoing immune response. Control of the inflammatory response is exerted on a number of levels (for review see Henderson B., and Wilson M. 1998. In “Bacteria-Cytokine interactions in health and disease. Portland Press, 79-130).
  • the controlling factors include cytokines, hormones (e.g. hydrocortisone), prostaglandins, reactive intermediates and leukotrienes. Cytokines are low molecular weight biologically active proteins that are involved in the generation and control of immunological and inflammatory responses, while also regulating development, tissue repair and haematopoiesis.
  • TNF ⁇ is a pivotal proinflammatory cytokine as it initiates a cascade of cytokines and biological effects resulting in the inflammatory state. Therefore, agents which inhibit TNF ⁇ are currently being used for the treatment of inflammatory diseases, e.g. infliximab.
  • Pro-inflammatory cytokines are thought to play a major role in the pathogenesis of many inflammatory diseases, including inflammatory bowel disease (IBD).
  • IBD inflammatory bowel disease
  • Current therapies for treating IBD are aimed at reducing the levels of these pro-inflammatory cytokines, including IL-8 and TNF ⁇ . It has been suggested that such therapies may also play a significant role in the treatment of systemic inflammatory diseases such as rheumatoid arthritis.
  • Humans fed with yoghurt containing Bifidobacterium longum infantis UCC35624 have shown marked decreases in their systemic levels of IL-8. This strain may therefore have potential application in the treatment of a range of inflammatory diseases, particularly if used in combination with current anti-inflammatory therapies, such as non-steroid anti-inflammatory drugs (NSA/Ds) or Infliximab.
  • NSA/Ds non-steroid anti-inflammatory drugs
  • Infliximab Infliximab.
  • the barrier function of the intestinal epithelium can be diminished during nervous (acetylcholine) and immune (histamine) mediated secretion.
  • Certain bacterial toxins may also induce Ca2+ and PKC dependent secretion and thereby can disturb the epithelial barrier (Ganguly N K and Kaur T. Indian J Med Res 1996;104:28-37, Groot J A. Vet Q 1998;20(S3):45-9).
  • Several studies have examined the prevention and treatment of diarrhoea using probiotic bacteria.
  • FIGS. 14 and 15 illustrate the lower intestine of treated and untreated SCID mice.
  • the lower intestine shown includes the caecum 2 , intestine 3 and anus 5 .
  • FIG. 14 the mice were treated with Bifidobacterium longum infantis UCC 35624 and it is apparent that solid stools 4 have been retained in the intestine.
  • FIG. 15 shows the untreated mouse intestine 3 , characteristically inflamed. No water absorption has occurred so that no solid stools are retained resulting in diarrhoea.
  • the anti-diarrhoeal effect observed may be related to the anti-inflammatory activity, possibly mediated via cAMP modulation.
  • Cyclic AMP-dependent Cl-secretion is the major secretory pathway in the human intestine (Brzuszczak IM, et al., J. Gastroenterol. Hepatol. 1996;11(9):804-10). It can be inferred that the anti-diarrhoeal effect of Bifidobacterium longum infantis UCC 35624 is not restricted just to diarrhoea resulting from gastrointestinal inflammation, but can be applied to the general treatment of diarrhoeal disease.
  • the immune system has a large repertoire of specificities expressed by B and T cells. Some of these specificities will be directed to self-components. Self-recognition is normally controlled by clonal deletion and inactivation of self-reactive lymphocytes. However, there is a constant background of autoimmunity with antibodies to many proteins being found in serum. A breakdown in the self-nonself recognition system results in autoimmunity. When autoimmune disease does occur, the resulting immune response damages the tissue bearing the offending antigen. Immune complex deposition, type II hypersensitivity and cell-mediated reactions are the most important mechanisms by which immunopathological damage occurs.
  • autoimmune diseases include, but are not limited to, systemic lupus erytematosus, rheumatoid arthritis, insulin dependent diabetes mellitus, myasthenia gravis and pernicious anaemia.
  • Bifidobacterium longum infantis and Lactobacillus salivarius subsp. salivarius are immunomodulatory bacteria. Thus, consumption either as single components or in combination of these bacteria by patients suffering from autoimmune disease may restrict organ damage and help restore normal body homeostasis.
  • intestinal bacteria can produce, from dietary compounds, substances with genotoxic, carcinogenic and tumour-promoting activity and gut bacteria can activate pro-carcinogens to DNA reactive agents (Rowland I. R. (1995). Toxicology of the colon: role of the intestinal microflora. In: Gibson G. R. (ed). Human colonic bacteria: role in nutrition, physiology and pathology, pp 155-174. Boca Raton CRC Press).
  • species of Bifidobacteria and Lactobacillus have low activities of xenobiotic metabolising enzymes compared to other populations within the gut such as bacteroides, eubacteria and clostridia (Saito Y., et al., Microb. Ecol. Health Dis., 1992;5, 105-110). Therefore, increasing the number of lactic acid bacteria in the gut could beneficially modify the levels of these enzymes.
  • probiotic organisms are accomplished by the ingestion of the microorganism in a suitable carrier. It would be advantageous to provide a medium that would promote the growth of these probiotic strains in the large bowel.
  • the addition of one or more oligosaccharides, polysaccharides, or other prebiotics enhances the growth of lactic acid bacteria in the gastrointestinal tract (Gibson, G R. Br. J. Nutr. 1998;80 (4):S209-12).
  • Prebiotics refers to any non-viable food component that is specifically fermented in the colon by indigenous bacteria thought to be of positive value, e.g. bifidobacteria, lactobacilli.
  • Types of prebiotics may include those which contain fructose, xylose, soya, galactose, glucose and mannose.
  • the combined administration of a probiotic strain with one or more prebiotic compounds may enhance the growth of the administered probiotic in vivo resulting in a more pronounced health benefit, and is termed synbiotic.
  • the Bifidobacterium may be administered prophylactically or as a method of treatment either on its own or with other probiotic and/or prebiotic materials as described above.
  • the bacteria may be used as part of a prophylactic or treatment regime using other active materials such as those used for treating inflammation or other disorders, especially those of the gastrointestinal tract.
  • Such combinations may be administered in a single formulation or as separate formulations administered at the same or different times and using the same or different routes of administration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US09/903,681 1999-01-15 2001-07-13 Bifidobacterium in the treatment of inflammatory disease Abandoned US20020006432A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US10/376,602 US20030170217A1 (en) 1999-01-15 2003-03-03 Bifidobacterium in the treatment of inflammatory disease
US10/388,652 US20030215467A1 (en) 1999-01-15 2003-03-17 Bifidobacteriumin the treatment of inflammatory disease
US10/783,020 US7195906B2 (en) 1999-01-15 2004-02-23 Bifidobacterium in the treatment of inflammatory disease
US10/956,330 US20050214272A1 (en) 1999-01-15 2004-10-04 Bifidobacterium in the treatment of inflammatory disease
US10/975,353 US20060002908A1 (en) 1999-01-15 2004-10-29 Bifidobacterium in the treatment of inflammatory disease
US11/478,545 US20070141039A1 (en) 1999-01-15 2006-06-29 Bifidobacterium in the treatment of inflammatory disease
US11/699,115 US20080057109A1 (en) 1999-01-15 2007-01-29 Bifidobacterium in the treatment of inflammatory disease
US12/123,052 US20080311080A1 (en) 1999-01-15 2008-05-19 Bifidobacterium in the treatment of inflammatory disease
US12/479,364 US20100112003A1 (en) 1999-01-15 2009-06-05 Bifidobacterium in the treatment of inflammatory disease

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IE990033 1999-01-15
IE990033A IE990033A1 (en) 1999-01-15 1999-01-15 Bifidobacterium longum infantis in the treatment of inflammatory bowel disease
IE990782 1999-09-20
IE990782 1999-09-20
PCT/IE2000/000008 WO2000042168A2 (en) 1999-01-15 2000-01-17 Bifidobacterium in the treatment of inflammatory disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/IE2000/000008 Continuation WO2000042168A2 (en) 1999-01-15 2000-01-17 Bifidobacterium in the treatment of inflammatory disease

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/376,602 Division US20030170217A1 (en) 1999-01-15 2003-03-03 Bifidobacterium in the treatment of inflammatory disease
US10/388,652 Division US20030215467A1 (en) 1999-01-15 2003-03-17 Bifidobacteriumin the treatment of inflammatory disease
US10/783,020 Continuation US7195906B2 (en) 1999-01-15 2004-02-23 Bifidobacterium in the treatment of inflammatory disease

Publications (1)

Publication Number Publication Date
US20020006432A1 true US20020006432A1 (en) 2002-01-17

Family

ID=26320235

Family Applications (13)

Application Number Title Priority Date Filing Date
US09/903,681 Abandoned US20020006432A1 (en) 1999-01-15 2001-07-13 Bifidobacterium in the treatment of inflammatory disease
US10/241,797 Abandoned US20030166257A1 (en) 1999-01-15 2002-09-12 Use of Lactobacillus salivarius
US10/376,602 Abandoned US20030170217A1 (en) 1999-01-15 2003-03-03 Bifidobacterium in the treatment of inflammatory disease
US10/388,652 Abandoned US20030215467A1 (en) 1999-01-15 2003-03-17 Bifidobacteriumin the treatment of inflammatory disease
US10/783,020 Expired - Lifetime US7195906B2 (en) 1999-01-15 2004-02-23 Bifidobacterium in the treatment of inflammatory disease
US10/804,223 Abandoned US20050084482A1 (en) 1999-01-15 2004-03-19 Use of lactobacillus salivarius
US10/956,330 Abandoned US20050214272A1 (en) 1999-01-15 2004-10-04 Bifidobacterium in the treatment of inflammatory disease
US10/975,353 Abandoned US20060002908A1 (en) 1999-01-15 2004-10-29 Bifidobacterium in the treatment of inflammatory disease
US11/311,632 Abandoned US20060292133A1 (en) 1999-01-15 2005-12-20 Use of lactobacillus salivarius
US11/478,545 Abandoned US20070141039A1 (en) 1999-01-15 2006-06-29 Bifidobacterium in the treatment of inflammatory disease
US11/699,115 Abandoned US20080057109A1 (en) 1999-01-15 2007-01-29 Bifidobacterium in the treatment of inflammatory disease
US12/123,052 Abandoned US20080311080A1 (en) 1999-01-15 2008-05-19 Bifidobacterium in the treatment of inflammatory disease
US12/479,364 Abandoned US20100112003A1 (en) 1999-01-15 2009-06-05 Bifidobacterium in the treatment of inflammatory disease

Family Applications After (12)

Application Number Title Priority Date Filing Date
US10/241,797 Abandoned US20030166257A1 (en) 1999-01-15 2002-09-12 Use of Lactobacillus salivarius
US10/376,602 Abandoned US20030170217A1 (en) 1999-01-15 2003-03-03 Bifidobacterium in the treatment of inflammatory disease
US10/388,652 Abandoned US20030215467A1 (en) 1999-01-15 2003-03-17 Bifidobacteriumin the treatment of inflammatory disease
US10/783,020 Expired - Lifetime US7195906B2 (en) 1999-01-15 2004-02-23 Bifidobacterium in the treatment of inflammatory disease
US10/804,223 Abandoned US20050084482A1 (en) 1999-01-15 2004-03-19 Use of lactobacillus salivarius
US10/956,330 Abandoned US20050214272A1 (en) 1999-01-15 2004-10-04 Bifidobacterium in the treatment of inflammatory disease
US10/975,353 Abandoned US20060002908A1 (en) 1999-01-15 2004-10-29 Bifidobacterium in the treatment of inflammatory disease
US11/311,632 Abandoned US20060292133A1 (en) 1999-01-15 2005-12-20 Use of lactobacillus salivarius
US11/478,545 Abandoned US20070141039A1 (en) 1999-01-15 2006-06-29 Bifidobacterium in the treatment of inflammatory disease
US11/699,115 Abandoned US20080057109A1 (en) 1999-01-15 2007-01-29 Bifidobacterium in the treatment of inflammatory disease
US12/123,052 Abandoned US20080311080A1 (en) 1999-01-15 2008-05-19 Bifidobacterium in the treatment of inflammatory disease
US12/479,364 Abandoned US20100112003A1 (en) 1999-01-15 2009-06-05 Bifidobacterium in the treatment of inflammatory disease

Country Status (22)

Country Link
US (13) US20020006432A1 (https=)
EP (4) EP1141235B1 (https=)
JP (2) JP4706016B2 (https=)
CN (3) CN1245994C (https=)
AT (3) ATE326525T1 (https=)
AU (3) AU3071500A (https=)
BR (2) BRPI0007481B8 (https=)
CA (3) CA2359334C (https=)
DE (3) DE60028003T2 (https=)
DK (2) DK1143985T3 (https=)
ES (2) ES2265331T3 (https=)
HK (1) HK1044964B (https=)
ID (2) ID29150A (https=)
IE (1) IE20000033A1 (https=)
IL (3) IL144184A0 (https=)
MX (2) MXPA01007144A (https=)
NO (2) NO327792B1 (https=)
NZ (2) NZ529353A (https=)
PT (1) PT1141235E (https=)
RU (2) RU2279282C2 (https=)
TR (2) TR200102058T2 (https=)
WO (3) WO2000042168A2 (https=)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092163A1 (en) * 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
US20040110270A1 (en) * 2002-12-05 2004-06-10 Veronique Dennin Bacterial composition and its use
WO2004067731A1 (en) * 2003-01-31 2004-08-12 Probi Ab New strains of bifidobacterium having the ability to produce glutamine
US20050025745A1 (en) * 2000-09-21 2005-02-03 Minoru Fujimori Anaerobic bacterium as a drug for cancer gene therapy
US20050074441A1 (en) * 1999-01-15 2005-04-07 Enterprise Ireland (Trading As Bioresearch Ireland) Bifidobacterium in the treatment of inflammatory disease
US7018629B2 (en) 2002-10-06 2006-03-28 The Bio Balance Corporation Probiotic compositions for the treatment of inflammatory bowel disease
US20070148147A1 (en) * 2002-12-05 2007-06-28 Veronique Dennin Bacterial composition and its use
US20080038228A1 (en) * 2003-10-01 2008-02-14 Danisco A/S Method
US20080206213A1 (en) * 2007-02-28 2008-08-28 Bristol-Myers Squibb Company Method for reducing or preventing systemic inflammation
US20090170772A1 (en) * 2006-03-31 2009-07-02 Morinaga Milk Industry Co., Ltd. Interleukin production regulator, pharmaceutical composition or food comprising the interleukin production regulator, and method for production of the interleukin production regulator
US8767209B2 (en) 2010-06-02 2014-07-01 Beioptics Technology Co., Ltd. Broadband polarization spectrometer with inclined incidence and optical measurement system
US20150190437A1 (en) * 2003-12-19 2015-07-09 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
CN111386124A (zh) * 2017-11-01 2020-07-07 表飞鸣制药株式会社 非甾体抗炎药及质子泵抑制剂所诱发的小肠损伤的预防或治疗剂
WO2021021765A1 (en) * 2019-07-26 2021-02-04 Evolve Biosystems, Inc. Nutritive compositions with bioactive proteins
CN113943681A (zh) * 2020-11-12 2022-01-18 江南大学 一株降低炎症反应且具有缓解便秘作用的长双歧杆菌
WO2022103138A1 (ko) * 2020-11-13 2022-05-19 주식회사 비피도 비피도박테리움 롱검 rapo (kctc13773bp)를 포함하는 암 예방 또는 치료용 조성물
US11825856B2 (en) * 2018-03-28 2023-11-28 Morinaga Milk Industry Co., Ltd. Composition for preventing or improving functional gastrointestinal disorders, and, pharmaceutical composition, food/beverage composition, and method of preventing or improving functional gastrointestinal disorders using the composition for preventing or improving functional gastrointestinal disorders

Families Citing this family (219)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US7029702B2 (en) * 1998-07-07 2006-04-18 Ritter Natural Sciences Llc Method for increasing lactose tolerance in mammals exhibiting lactose intolerance
CA2378620A1 (en) * 1999-08-09 2001-02-15 Pinaki Panigrahi Pro-gut maturation and anti-inflammatory effects of lactobacillus and lactobacillus secreted proteins, carbohydrates and lipids
EP1409010A4 (en) * 2000-07-03 2005-06-29 Probendo Pty Ltd TREATMENT   OF   endotoxemia   AND   OF   DISORDERS   ASSOCIATED   BY   OF   PROBIOTICS
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
BRPI0114400B8 (pt) 2000-10-06 2021-05-25 Nestle Sa uso de bactéria de ácido lático probiótica para equilibrar o sistema imunológico da pele
IT1320772B1 (it) * 2000-11-02 2003-12-10 Proge Farm Srl Composizione farmaceutica a base di agenti attivi contro la candidaper il trattamento di disturbi della mucosa orale e intestinale
JPWO2002061118A1 (ja) * 2001-02-01 2004-06-03 株式会社ヤクルト本社 発酵乳飲食品中のビフィドバクテリウム属細菌の腸内到達度評価方法
EP1373475A2 (en) * 2001-04-02 2004-01-02 Alimentary Health Limited Immunotherapy based on dendritic cells
JP4671384B2 (ja) * 2001-05-15 2011-04-13 雪印乳業株式会社 新規乳酸菌株
EP1264893A1 (en) 2001-06-08 2002-12-11 Teagasc Dairy Products Research Centre CLA biosynthesis by bifidobacteria
PE20030274A1 (es) * 2001-07-26 2003-05-08 Alimentary Health Ltd Cepas de lactobacillus salivarius
JP5116194B2 (ja) * 2001-09-04 2013-01-09 株式会社ヤクルト本社 炎症性腸疾患予防治療剤
MXPA04001999A (es) * 2001-09-05 2004-07-16 Vsl Pharmaceuticals Inc Bacterias de acido lactico que comprende dinucleotidos de citosina-guanina no metilados para usarse en terapia.
GB0124580D0 (en) * 2001-10-12 2001-12-05 Univ Reading New composition
ATE322538T1 (de) 2001-12-07 2006-04-15 Morinaga Milk Industry Co Ltd Bifidobacterium longum
US6941649B2 (en) * 2002-02-05 2005-09-13 Force10 Networks, Inc. Method of fabricating a high-layer-count backplane
DE10206995B4 (de) * 2002-02-19 2014-01-02 Orthomol Pharmazeutische Vertriebs Gmbh Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika
AU2003250503A1 (en) * 2002-06-13 2003-12-31 University College Cork - National University Of Ireland, Cork Probiotic therapies using lactobacillus reuteri
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
US7105336B2 (en) * 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
JP2004189672A (ja) * 2002-12-11 2004-07-08 Gen Corp:Kk 抗下痢症組成物
US20040208863A1 (en) * 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
US20040197304A1 (en) 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US20040265279A1 (en) * 2003-05-08 2004-12-30 Timothy Dinan Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity
US7731976B2 (en) * 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US20060177424A1 (en) * 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US7759105B2 (en) * 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US7749509B2 (en) * 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
AU2004315890A1 (en) * 2003-12-04 2005-09-01 Burwell, Steve Mr. Methods and compositions for preventing biofilm formations, reducing existing biofilms, and for reducing existing biofilms, and for reducing populations of bacteria
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
WO2005072718A1 (ja) * 2004-01-28 2005-08-11 Kurume University 乳清発酵物を含有する医薬組成物
US7862808B2 (en) * 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
WO2006012536A2 (en) * 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
KR100568036B1 (ko) 2004-08-12 2006-04-07 하남주 장기능 활성화 및 면역기능 강화작용을 하는비피도박테리움 균주 및 이를 함유하는 생균제제
JP2006166829A (ja) * 2004-12-17 2006-06-29 Best Ecology:Kk アイスサプリメント及びその製造方法
WO2006097949A1 (en) * 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
EP1865795A1 (en) 2005-04-08 2007-12-19 Alimentary Health Limited Methods of use of orally administered probiotic bifidobacteria for human beauty benefits
AU2011205121B2 (en) * 2005-04-08 2012-07-05 Alimentary Health Ltd Method of use of orally administered probiotic bifidobacteria for human beauty benefits
US20060228448A1 (en) 2005-04-11 2006-10-12 The Iams Company Pet food compositions comprising two components
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
AU2006253007B2 (en) 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
EP2261323A1 (en) 2005-05-31 2010-12-15 The Iams Company Feline probiotic lactobacilli
EP1903893A1 (en) * 2005-07-20 2008-04-02 Unilever N.V. Edible product containing beneficial bacteria
ITMI20051510A1 (it) * 2005-08-02 2007-02-03 Proge Farm Srl Uso di specifici batteri lattici per la preparazione di composizioni iunomodulanti
RU2297835C1 (ru) * 2005-09-26 2007-04-27 Закрытое акционерное общество "Партнер" Препарат для лечения неинфекционных воспалительных болезней кишечника
US8246946B2 (en) * 2005-09-27 2012-08-21 Cobb & Associates Treatment of bipolar disorder utilizing anti-fungal compositions
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
WO2007133188A1 (en) * 2006-05-01 2007-11-22 Cobb & Company, Llp Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
WO2008053444A2 (en) 2006-11-01 2008-05-08 The Procter & Gamble Company Treating a respiratory condition with bifidobacterium
US7964238B2 (en) * 2007-01-29 2011-06-21 Guardian Industries Corp. Method of making coated article including ion beam treatment of metal oxide protective film
RU2436581C2 (ru) 2007-02-01 2011-12-20 Дзе Иамс Компани Способ уменьшения воспаления и снижения стресса у млекопитающего
KR20100014523A (ko) * 2007-02-22 2010-02-10 위르겐 슈레첸메이르 인간의 알레르기 반응을 예방, 억제 또는 제거하는 프로바이오틱 그램-양성 박테리아
US20080241226A1 (en) * 2007-03-27 2008-10-02 Abeln Susan L Methods and Kits For Administering Probiotics
EP2134833B1 (en) 2007-03-28 2016-03-09 Alimentary Health Limited Probiotic bifidobacterium strain
BRPI0809448A2 (pt) * 2007-03-28 2014-09-09 Alimentary Health Ltd Cepas de bifidobacterium probióticas
WO2008135959A1 (en) * 2007-05-04 2008-11-13 Alimentary Health Limited An exopolysaccharide
EP2522358B1 (en) 2007-06-27 2016-11-09 Laboratorios Ordesa, S.l. Peptides against rotavirus infection
JP2009057346A (ja) * 2007-09-03 2009-03-19 Kirin Holdings Co Ltd 免疫バランス調節用組成物
FR2921795B1 (fr) * 2007-10-03 2011-04-29 Gervais Danone Sa Utilisation d'une souche de bifidobacterium,pour la preparation d'une composition destinee a la prevention et/ou au traitement de manifestations de type allergique
AU2008328584A1 (en) * 2007-11-26 2009-06-04 Plant Bioscience Limited Novel polypeptides having endolysin activity and uses thereof
US20110223248A1 (en) * 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
EP2072053B1 (en) * 2007-12-21 2012-11-07 Compagnie Gervais Danone Method for decreasing abdominal girth by administering a bifidobacterium bacteria
ES2343499B1 (es) * 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
RU2375960C2 (ru) * 2008-01-28 2009-12-20 Федеральное государственное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии имени Г.Н. Габричевского Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека" (ФГУН МНИИЭМ им. Г.Н. Габрического Роспотребнадзора) Способ определения ареактогенного действия препарата пробиотика
EP2110028A1 (en) 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
EP2293802A4 (en) * 2008-06-25 2011-11-09 Ritter Pharmaceuticals Inc LACTOSE COMPOSITIONS HAVING REDUCED LACTOSE CONTENT
US9232813B2 (en) * 2008-07-07 2016-01-12 The Iams Company Probiotic supplement, process for making, and packaging
DK2318513T3 (da) * 2008-07-11 2012-10-22 Chr Hansen As Ny probiotisk bifidobacterium longum
RU2453320C2 (ru) * 2008-08-05 2012-06-20 Виктор Владимирович Чалов Композиция для перорального применения, содержащая непатогенные микроорганизмы, обладающая способностью нормализовать микрофлору кишечника (варианты)
MX2011002735A (es) * 2008-09-11 2011-04-12 Iams Company Alimento granulado para animales que tiene un nucleo basado en proteinas y metodos relacionados.
US20100074870A1 (en) * 2008-09-19 2010-03-25 Bristol-Myers Squibb Company Probiotic infant products
KR101057357B1 (ko) 2008-09-22 2011-08-17 광주과학기술원 유산균 및 콜라겐을 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물 및 식품 조성물
MX356598B (es) * 2008-11-11 2018-06-04 Alimentary Health Ltd Bifidobacterium longum.
EP2400839B1 (en) 2009-02-24 2016-09-07 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
GB0908949D0 (en) 2009-05-26 2009-07-01 Plant Bioscience Ltd Novel polypeptides having endolysin activity and uses thereof
US20100330151A1 (en) 2009-06-25 2010-12-30 Mary Elaine Freeland Method of Promoting Gastrointestinal Health Using a Combination of a Probiotic Microorganism and Chocolate
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US20110027412A1 (en) 2009-07-31 2011-02-03 Kris Eugene Spence Compositions and Methods for Promoting Gastrointestinal and/or Cardiovascular Health
TR201807143T4 (tr) 2009-08-25 2018-06-21 Nestec Sa Bifidobacterium longum ve fonksiyonel gastrointestinal bozukluklar.
WO2011027829A1 (ja) * 2009-09-02 2011-03-10 京都府公立大学法人 乳酸菌由来のｒｎａを有効成分とする組成物
JP2013507394A (ja) * 2009-10-09 2013-03-04 プロセラ インコーポレイテッド 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法
ES2610829T3 (es) * 2009-11-11 2017-05-03 Alimentary Health Limited Cepa de Bifidobacterium
EP2498789B1 (en) * 2009-11-11 2016-06-22 Alimentary Health Limited Probiotic bifidobacterium strain
CN102905712B (zh) 2010-01-28 2015-12-16 Ab－生物学有限公司 用于治疗肠炎的益生菌组合物
DK3564357T3 (da) 2010-02-01 2022-06-20 Rebiotix Inc Bakterieterapi mod clostridium difficile colitis
FR2955774A1 (fr) 2010-02-02 2011-08-05 Aragan Preparation destinee a traiter l'exces ponderal et les desordres associes et applications de ladite preparation
JP5852558B2 (ja) * 2010-03-26 2016-02-03 株式会社明治 腸管免疫の抑制剤のスクリーニング方法
RU2434058C1 (ru) * 2010-04-26 2011-11-20 Татьяна Александровна Левченко Штамм bifidobacterium longum, используемый для получения бифидосодержащей продукции
RU2451740C2 (ru) * 2010-04-26 2012-05-27 Татьяна Александровна Левченко ШТАММ Bifidobacterium longum АБД-7, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ БИФИДОСОДЕРЖАЩЕЙ ПРОДУКЦИИ
RU2451741C2 (ru) * 2010-04-26 2012-05-27 Татьяна Александровна Левченко ШТАММ Bifidobacterium longum АБД-3, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ БИФИДОСОДЕРЖАЩЕЙ ПРОДУКЦИИ
EP3202406A1 (en) 2010-04-28 2017-08-09 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
RU2427636C1 (ru) * 2010-05-14 2011-08-27 Татьяна Александровна Левченко ШТАММ Bifidobacterium longum, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ БИФИДОСОДЕРЖАЩЕЙ ПРОДУКЦИИ
RU2427626C1 (ru) * 2010-05-14 2011-08-27 Татьяна Александровна Левченко ШТАММ Bifidobacterium longum, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ БИФИДОСОДЕРЖАЩЕЙ ПРОДУКЦИИ
RU2427630C1 (ru) * 2010-05-28 2011-08-27 Татьяна Александровна Левченко ШТАММ Bifidobacterium longum, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ БИФИДОСОДЕРЖАЩЕЙ ПРОДУКЦИИ
RU2427629C1 (ru) * 2010-05-28 2011-08-27 Татьяна Александровна Левченко ШТАММ Bifidobacterium longum, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ БИФИДОСОДЕРЖАЩЕЙ ПРОДУКЦИИ
RU2427628C1 (ru) * 2010-05-28 2011-08-27 Татьяна Александровна Левченко ШТАММ Bifidobacterium longum, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ БИФИДОСОДЕРЖАЩЕЙ ПРОДУКЦИИ
WO2011148219A1 (en) * 2010-05-28 2011-12-01 Compagnie Gervais Danone Probiotic strains for use in improving the enteric nervous system
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
FR2962045B1 (fr) * 2010-07-05 2012-08-17 Bifinove Complexe macromoleculaire d'origine bacterienne et utilisation dudit complexe moleculaire pour prevenir et traiter les rhumatismes inflammatoires
EP3424515A3 (en) 2010-08-04 2019-06-19 Thomas Julius Borody Stool collection devices and methods for using them
BR112013010783A2 (pt) * 2010-11-11 2016-07-12 Nestec Sa confecções congeladas contendo micro-organismos probióticos
EP2481299B1 (en) 2011-01-31 2016-12-07 Dr. Fischer Gesundheitsprodukte GmbH Bifidobacterium bifidum strains for application in gastrointestinal diseases
US9968638B2 (en) 2011-03-09 2018-05-15 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
WO2012140636A1 (en) * 2011-04-11 2012-10-18 Alimentary Health Limited A probiotic formulation
RU2460777C1 (ru) * 2011-04-21 2012-09-10 Общество с ограниченной ответственностью "Бифилюкс" Штамм bifidobacterium longum, используемый для получения бифидосодержащей продукции
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
KR101355440B1 (ko) 2011-10-26 2014-02-05 주식회사한국야쿠르트 류마티스 관절염 예방 효능을 갖는 락토바실러스 헬베티쿠스 에이취와이7801 및 이를 유효성분으로 함유하는 제품
CN103131647B (zh) * 2011-11-29 2017-06-27 上海上药信谊药厂有限公司 婴儿双歧杆菌及其制剂
ES2993669T3 (en) 2011-12-01 2025-01-03 Univ Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
WO2013099883A1 (ja) * 2011-12-28 2013-07-04 株式会社山田養蜂場本社 IgA産生促進作用を有する新規乳酸菌及びその用途
WO2013107913A1 (en) 2012-01-19 2013-07-25 University College Cork - National University Of Ireland, Cork Gaba-producing culturable bacteria derived from the human gastrointestinal tract
EP2836224A4 (en) 2012-02-29 2015-12-16 Ethicon Endo Surgery Inc COMPOSITIONS OF BIOZOOSE AND RELATED METHODS
CA3008794C (en) 2012-03-29 2021-03-16 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
EP2925332A4 (en) 2012-08-20 2016-12-21 Boris Markosian PLACENTAL IMP THERAPY AGAINST CANCER
FR2999601B1 (fr) * 2012-12-17 2015-01-30 Urgo Lab Methode pour prevenir et/ou traiter les infections, colonisations ou maladies liees a staphylococcus aureus, pseudomonas aeruginosa, streptococcus pyogenes, enterococcus faecium, enterobacter cloacae, proteus mirabilis et/ou bacteroides fragilis
AU2014239883B2 (en) 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
KR101434220B1 (ko) * 2013-03-26 2014-08-28 삼육대학교산학협력단 다제내성균에 대한 저해 활성을 갖는 신규 유산균
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
KR102099503B1 (ko) 2013-06-05 2020-04-09 리바이오틱스, 인코퍼레이티드 미생물상 복원 요법(mrt) 조성물
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
JP6637885B2 (ja) 2013-07-21 2020-01-29 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオームの特性解明、モニタリング、および処置のための方法およびシステム
EP3097182A1 (en) 2014-01-24 2016-11-30 The Procter & Gamble Company Filaments comprising a microorganism and method for making same
US20150209468A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Hygiene article containing microorganism
US20150209469A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Web Comprising a Microorganism-Containing Fibrous Element and Methods for Making Same
CA2964480A1 (en) 2014-10-31 2016-05-06 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
EP3400953A1 (en) 2014-12-23 2018-11-14 4D Pharma Research Limited Pirin polypeptide and immune modulation
AR103260A1 (es) 2014-12-23 2017-04-26 4D Pharma Res Ltd Modulación inmunitaria
AU2016219070B2 (en) 2015-02-13 2020-06-11 Mars, Incorporated Pet food feeding system
AU2016255437B2 (en) 2015-04-28 2020-10-08 Mars, Incorporated Process of preparing a sterilized wet pet food product
BR112017024264B1 (pt) 2015-05-14 2022-07-12 Crestovo Holdings Llc Composições para transplante de flora fecal e métodos de preparação e utilização das mesmas, e dispositivos para sua administração
KR102534545B1 (ko) 2015-05-22 2023-05-18 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 자폐 스펙트럼 장애 및 관련된 증상을 치료하는 방법
PE20180673A1 (es) * 2015-06-01 2018-04-19 Univ Chicago Tratamiento contra el cancer por manipulacion de la microflora comensal
US20160354507A1 (en) 2015-06-07 2016-12-08 The Procter & Gamble Company Article of commerce containing absorbent article
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
ES2889902T3 (es) 2015-06-09 2022-01-14 Rebiotix Inc Métodos de fabricación de composiciones para terapia de restauración de la microbiota (TRM)
WO2016203221A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
NZ737752A (en) 2015-06-15 2022-02-25 4D Pharma Res Ltd Compositions comprising bacterial strains
SMT201900588T1 (it) 2015-06-15 2019-11-13 4D Pharma Res Limited Blautia stercoris e wexlerae per uso nel trattamento di malattie infiammatorie ed autoimmuni
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
US20170020750A1 (en) 2015-07-23 2017-01-26 The Procter & Gamble Company Patch containing microorganism
US20180280453A1 (en) 2015-08-27 2018-10-04 Alimentary Health Limited Use of bifidobacterium longum and an exopolysaccharide produced thereby
EP3341082B1 (en) 2015-08-27 2020-12-16 PrecisionBiotics Group Limited Bifidobacterium longum
CN108367031A (zh) 2015-10-05 2018-08-03 瑞士达沃斯高山气候和医学研究院 嗜黏蛋白阿克曼氏菌用于治疗炎症病况的用途
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CN108513545B (zh) 2015-11-20 2020-11-03 4D制药研究有限公司 包含细菌菌株的组合物
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
ME03487B (me) 2016-03-04 2020-01-20 4D Pharma Plc Kompozicije koje sadrže blautia bakterijske sojeve za liječenje visceralne hipersenzitivnosti
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
JP7058602B2 (ja) * 2016-03-04 2022-04-22 カリフォルニア インスティチュート オブ テクノロジー 新規ゲルマノシリケート組成物及びその製造方法
RU2659240C2 (ru) * 2016-05-23 2018-06-29 федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный университет" (КемГУ) Способ получения функционального продукта питания для реабилитации онкологических больных
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
IT201600121481A1 (it) * 2016-11-30 2018-05-30 Sintal Dietetics Srl L. salivarius sgl03: attività probiotiche e produzione di proteine antimicrobiche
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CN107043705A (zh) * 2016-12-30 2017-08-15 大连医科大学 用于建立临床营养菌种资源库的益生菌筛选方法
CA3052134C (en) * 2017-01-31 2023-01-03 University-Industry Cooperation Group Of Kyung Hee University Novel lactic acid bacteria and use thereof
EP3589726A1 (en) 2017-02-28 2020-01-08 Alimentary Health Limited Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
EP3606541A1 (en) 2017-04-05 2020-02-12 Crestovo Holdings LLC Compositions and methods for treating parkinson's disease (pd) and related disorders
DK3630136T3 (da) 2017-05-22 2021-05-25 4D Pharma Res Ltd Sammensætninger, der omfatter bakteriestammer
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
JP2020521760A (ja) 2017-05-26 2020-07-27 クレストヴォ・ホールディングス・エルエルシー 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法
CA3066189A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
SMT202000555T1 (it) 2017-06-14 2020-11-10 4D Pharma Res Limited Composizioni comprendenti un ceppo batterico del genere megaspaera e loro usi
SMT202000695T1 (it) 2017-06-14 2021-01-05 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
TW201906620A (zh) 2017-07-05 2019-02-16 美商艾弗洛生物科技股份有限公司 使用動物雙岐桿菌乳亞種 (bifidobacterium animalis ssp. lactis) 治療癌症之組合物及方法
JP2020530494A (ja) * 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド． 健康な腸バリアを維持及び回復するための組成物及び方法
JP2020532515A (ja) 2017-08-30 2020-11-12 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオーム関連障害の処置のための方法および組成物
RU2665173C1 (ru) * 2017-09-18 2018-08-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Оренбургский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ профилактики атопического дерматита у младенцев путем модуляции микробного механизма гистаминообразования
KR102024883B1 (ko) 2017-11-24 2019-09-24 주식회사 고바이오랩 락토바실러스 퍼멘텀 kbl 375 균주 및 그 용도
DK3517119T3 (da) 2018-01-26 2021-11-15 Probisearch S L U Sammensætning omfattende ny lactobacillus salivarius-stamme og fremgangsmåde til forebyggelse og behandling af otitis og infektioner i de øvre luftveje
DK3745870T3 (da) * 2018-01-29 2023-02-20 Prec Group Limited Et kombinationsprodukt til profylakse og behandling af irritabel tarmsyndrom
RU2670054C1 (ru) * 2018-04-24 2018-10-17 Федеральное государственное бюджетное учреждение науки Институт клеточного и внутриклеточного симбиоза Уральского отделения Российской академии наук Штамм бактерий Bifidobacterium bifidum ICIS-310 - продуцент ингибитора провоспалительного цитокина INF-γ
MY202164A (en) 2018-05-09 2024-04-09 Kobiolabs Inc Lactobacillus paracasei strain and use thereof
CN113151036B (zh) * 2018-05-11 2024-08-23 韩国亿诺生物有限公司 具有预防或治疗癌症的效果的新型菌株
KR102138834B1 (ko) 2018-05-23 2020-07-29 주식회사 고바이오랩 락토바실러스 가세리 kbl697 균주 및 그 용도
WO2019227414A1 (zh) * 2018-05-31 2019-12-05 深圳华大生命科学研究院 一种组合物及其应用
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
EP3823651A4 (en) 2018-07-19 2022-04-27 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MICROBIAL TRANSPLANTATION
CN109486700A (zh) * 2018-08-31 2019-03-19 石家庄君乐宝乳业有限公司 副干酪乳杆菌n1115预防结肠炎的应用及相应的益生菌粉、应用
EP3856212A1 (en) 2018-09-27 2021-08-04 Finch Therapeutics Holdings LLC Compositions and methods for treating epilepsy and related disorders
ES2752798B2 (es) * 2018-10-05 2020-08-12 Consejo Superior Investigacion Cepa de Bifidobacterium longum sub. infantis y uso de la misma
KR102074445B1 (ko) * 2018-12-12 2020-02-06 주식회사 비피도 류마티스관절염 개선, 예방 또는 치료를 위한 비피도박테리움 롱검 rapo 균주 및 이를 포함하는 조성물
PH12021553137A1 (en) 2019-07-19 2022-07-25 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders
KR102224072B1 (ko) * 2019-08-19 2021-03-10 주식회사 빙그레 면역 조절능력과 혈중콜레스테롤 감소 능력이 모두 뛰어난 비피도박테리엄 롱검 아종 균주 및 이의 용도
CN110547915A (zh) * 2019-08-29 2019-12-10 云南白药清逸堂实业有限公司 应用益生菌的卫生棉制品及其制备方法
CN110452860A (zh) * 2019-09-24 2019-11-15 厦门大学 一种唾液链球菌及其在治疗炎症性肠病药物中的应用
WO2021180973A1 (en) 2020-03-13 2021-09-16 Precisionbiotics Group Limited Bifidobacterium longum
TWI748395B (zh) * 2020-03-31 2021-12-01 豐華生物科技股份有限公司 緩解過敏以及提升運動表現之組合物及其用途
EP4285997A4 (en) * 2021-01-26 2025-04-16 Megmilk Snow Brand Co. Ltd. COMPOSITION TO IMPROVE JOINT FUNCTION
CN114317310B (zh) * 2021-03-31 2023-09-22 江苏蓝泽生物科技有限公司 一种抗过敏的婴儿双歧杆菌制剂及其制备方法
CN114558037B (zh) * 2022-02-24 2023-08-15 同济大学 Akk和ls在制备提高认识水平的抗衰老产品中的应用
CN115725456B (zh) * 2022-10-11 2024-06-21 四川大学 一种唾液乳杆菌及其应用
WO2024248549A1 (ko) * 2023-06-01 2024-12-05 재단법인 아산사회복지재단 락토바실러스 살리바리우스 또는 박테로이데스 플레비우스를 포함하는 면역항암제 치료 반응성 및 예후 예측용 바이오마커 및 이를 이용한 면역항암제 치료 반응성 및 예후 예측 방법
CN116574659A (zh) * 2023-06-14 2023-08-11 江南大学 一株可缓解类风湿性关节炎的长双歧杆菌婴儿亚种及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5711977A (en) * 1996-05-06 1998-01-27 Food Industry Research And Development Institute Bifidobacteria strains with acid, bile salt and oxygen tolerance and their culture method
US6077504A (en) * 1996-06-28 2000-06-20 Cavaliere Ved. Vesley; Renata Maria Anna Enteral dietary compositions comprising a mixture of live lactic bacteria consisting of Streptococcus thermophilus, Bifidobacterium longum and Bifidobacterium infantis
US6368591B2 (en) * 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6038372B2 (ja) 1975-04-09 1985-08-31 日清製粉株式会社 犬の下痢予防および治療方法
JPS55113718A (en) * 1979-02-27 1980-09-02 Yakult Honsha Co Ltd Antitumor agent
US4435389A (en) * 1980-07-07 1984-03-06 Kabushiki Kaisha Yakult Honsha Composition for promoting growth of bifidobacteria
JPS59118712A (ja) * 1982-12-27 1984-07-09 Morinaga Milk Ind Co Ltd 抗腫瘍剤及びその製造法
US4678773A (en) * 1983-08-26 1987-07-07 Chugai Seiyaku Kabushiki Kaisha Antitumor agent
US4839281A (en) * 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
JPH0696538B2 (ja) * 1985-12-19 1994-11-30 株式会社アドバンス 抗発癌剤
SU1817285A1 (ru) * 1986-06-05 1996-08-10 Восточно-Сибирский технологический институт Способ приготовления закваски для производства кисломолочных продуктов
JPS63196521A (ja) * 1987-02-10 1988-08-15 Yakult Honsha Co Ltd 腫瘍細胞障害性因子誘起剤
US5352586A (en) * 1987-05-01 1994-10-04 Biogaia Ab Method of determining the presence of an antibiotic produced by Lactobacillus reuteri
DK686187D0 (da) 1987-12-23 1987-12-23 Hansens Chr Bio Syst Veterinaert praeparat
US5443826A (en) * 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
DE68928665T2 (de) 1988-08-02 1998-11-12 Gastro Services Pty Ltd Behandlung von gastro-intestinalen krankheiten
SE8900546D0 (sv) 1989-02-17 1989-02-17 Bioinvent Int Ab Medel foer inhibering av patogeners adhesion tillvaext och /eller oeverlevnad
NZ244737A (en) 1989-02-21 1993-09-27 Viskase Corp Food packaging polymeric film containing antibiotic material; method of treating foodstuff and food casing therefor
JP2932283B2 (ja) * 1989-07-14 1999-08-09 雪印乳業株式会社 ビフィズス菌を含有する醗酵乳の製造方法
DE4033996A1 (de) * 1990-10-25 1992-04-30 Karl Heinz Hoelzel Enzymatisches stoffwechselprodukt zur symbioselenkung und verfahren zu seiner herstellung
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
DE69219768T2 (de) * 1992-07-06 1997-08-28 Societe Des Produits Nestle S.A., Vevey Milchbakterien
RU2048517C1 (ru) * 1992-09-24 1995-11-20 Институт микробиологии Штамм бактерий bifidobacterium longum, используемый для приготовления бактериальных препаратов и кисломолочных продуктов
US5413785A (en) * 1993-01-27 1995-05-09 New England Deaconess Hospital Corp. Methodology employing lactobacillus GG for reduction of plasma endotoxin levels circulating in-vivo
RU2031586C1 (ru) * 1993-02-05 1995-03-27 Тамара Георгиевна Извекова Биологически активный кисломолочный продукт "ацидолакт-наринэ" и способ его получения
JPH0782158A (ja) * 1993-09-16 1995-03-28 Yakult Honsha Co Ltd 抗腫瘍剤
JP3623977B2 (ja) * 1993-10-29 2005-02-23 明治乳業株式会社 潰瘍性大腸炎治療剤
JPH07265064A (ja) * 1993-11-23 1995-10-17 Taketoshi Yamada 腸内細菌叢改善組成物
WO1996002255A1 (en) * 1994-07-15 1996-02-01 Taiyo Kagaku Co., Ltd. Medicinal composition containing sialic acid derivative
JP2780154B2 (ja) * 1995-02-17 1998-07-30 株式会社ヤクルト本社 ヨーグルト
JPH092959A (ja) * 1995-06-16 1997-01-07 Yakult Honsha Co Ltd ＩｇＥ抗体産生抑制剤および抗アレルギー剤
RU2091075C1 (ru) * 1995-06-28 1997-09-27 Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Комплексный бактериальный препарат для лечения и профилактики желудочно-кишечных заболеваний животных
JP4021951B2 (ja) * 1996-03-01 2007-12-12 わかもと製薬株式会社 乳酸菌を有効成分とする抗胃炎剤、抗潰瘍剤および醗酵食品
JPH09241179A (ja) * 1996-03-01 1997-09-16 Meiji Seika Kaisha Ltd ビフィドバクテリウム属菌由来の水溶性免疫賦活物質およびその精製法
US5902578A (en) 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
MXPA99007378A (es) * 1997-02-11 2005-04-19 Entpr Ireland Cepas probioticas de lactobacillus salivarius y agentes antimicrobianos obtenidos a partir de lasmismas.
US6132710A (en) * 1997-03-17 2000-10-17 Probiotix, Inc. Preventing/treating neonatal NEC by administering lactobacillus salivarius and lactobacillus plantarum or a combination thereof
RU2109054C1 (ru) 1997-04-01 1998-04-20 Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского Консорциум бифидобактерий bifidobacterium bifidum 791, b. longum b 379 m, b. breve 79-119, b. infantis 73-15, b. adolescentis г 7513 для приготовления кисломолочных, неферментированных пищевых продуктов и бактерийных препаратов
CN1178703A (zh) * 1997-08-06 1998-04-15 北京东方百信生物技术有限公司 幼儿胃肠安制剂及其生产工艺
EP0904784A1 (en) 1997-09-22 1999-03-31 N.V. Nutricia Probiotic nutritional preparation
US5902743A (en) * 1998-03-20 1999-05-11 Wisconsin Alumni Research Foundation Probiotic bifidobacterium strain
FI980782A7 (fi) 1998-04-03 1999-10-04 Timo Korhonen Epiteelisoluihin sitoutuva proteiinialue ja sitä koodaava DNA-sekvenssi
EP1082021B1 (en) 1998-05-29 2002-07-24 Enterprise Ireland (trading as Bioresearch Ireland) Process for the manufacture of probiotic cheese
DE69914932T2 (de) * 1998-10-20 2004-12-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
AUPQ415899A0 (en) 1999-11-19 1999-12-16 Vasse Research Institute Pty Ltd Compositions for and methods of treatment of allergic diseases
SI1312667T1 (sl) 2000-08-25 2009-04-30 Wakamoto Pharma Co Ltd Probiotiäśni produkti, ki vsebujejo sev l. salivarius
US6618973B2 (en) * 2001-05-15 2003-09-16 Ned H. Nelson Banner holder

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5711977A (en) * 1996-05-06 1998-01-27 Food Industry Research And Development Institute Bifidobacteria strains with acid, bile salt and oxygen tolerance and their culture method
US6077504A (en) * 1996-06-28 2000-06-20 Cavaliere Ved. Vesley; Renata Maria Anna Enteral dietary compositions comprising a mixture of live lactic bacteria consisting of Streptococcus thermophilus, Bifidobacterium longum and Bifidobacterium infantis
US6368591B2 (en) * 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050214272A1 (en) * 1999-01-15 2005-09-29 Enterprise Ireland (Trading As Bioresearch Ireland) Bifidobacterium in the treatment of inflammatory disease
US20080057109A1 (en) * 1999-01-15 2008-03-06 University College Cork-National University Of Ireland, Cork & Enterprise Ireland (Trading As Bifidobacterium in the treatment of inflammatory disease
US20070141039A1 (en) * 1999-01-15 2007-06-21 University College Cork - National University Of Ireland, Cork Bifidobacterium in the treatment of inflammatory disease
US7195906B2 (en) 1999-01-15 2007-03-27 Enterprise Ireland (Trading As Bioresearch Ireland) Bifidobacterium in the treatment of inflammatory disease
US20050074441A1 (en) * 1999-01-15 2005-04-07 Enterprise Ireland (Trading As Bioresearch Ireland) Bifidobacterium in the treatment of inflammatory disease
US7740835B2 (en) 2000-09-21 2010-06-22 Anaeropharma Science Inc. Anaerobic bacterium as a drug for cancer gene therapy
US20050025745A1 (en) * 2000-09-21 2005-02-03 Minoru Fujimori Anaerobic bacterium as a drug for cancer gene therapy
US20030092163A1 (en) * 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
US20060121015A1 (en) * 2001-07-26 2006-06-08 Alimentary Health Limited Probiotic bifidobacterium strains
US7018629B2 (en) 2002-10-06 2006-03-28 The Bio Balance Corporation Probiotic compositions for the treatment of inflammatory bowel disease
US7740838B2 (en) * 2002-12-05 2010-06-22 Danisco A/S Bacterial composition and its use
US7179460B2 (en) * 2002-12-05 2007-02-20 Danisco A/S Bacterial composition and its use
US8071086B2 (en) 2002-12-05 2011-12-06 Danisco A/S Bacterial composition and its use
WO2004052462A1 (fr) * 2002-12-05 2004-06-24 Danisco France Composition comprenant des lactobacillus ou des bifidobacterium et son utilisation
US20070148147A1 (en) * 2002-12-05 2007-06-28 Veronique Dennin Bacterial composition and its use
US20070148148A1 (en) * 2002-12-05 2007-06-28 Veronique Dennin Bacterial composition and its use
US20100322964A1 (en) * 2002-12-05 2010-12-23 Dennin Veronique Bacterial composition and its use
FR2848115A1 (fr) * 2002-12-05 2004-06-11 Rhodia Chimie Sa Composition de bacteries et son utilisation
US20040110270A1 (en) * 2002-12-05 2004-06-10 Veronique Dennin Bacterial composition and its use
AU2003298411B2 (en) * 2002-12-05 2009-02-19 Dupont Nutrition Biosciences Aps Composition comprising lactobacilli or bifidobacteria and use thereof
US7947482B2 (en) 2003-01-31 2011-05-24 Probi Ab Strains of bifidobacterium having the ability to produce glutamine
US20060269533A1 (en) * 2003-01-31 2006-11-30 Goran Molin New strains of bifidobacterium having the ability to produce glutamine
WO2004067731A1 (en) * 2003-01-31 2004-08-12 Probi Ab New strains of bifidobacterium having the ability to produce glutamine
US20080038228A1 (en) * 2003-10-01 2008-02-14 Danisco A/S Method
US20150190437A1 (en) * 2003-12-19 2015-07-09 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US9821015B2 (en) * 2003-12-19 2017-11-21 Mars, Incorporated Methods of use of probiotic bifidobacteria for companion animals
US20090170772A1 (en) * 2006-03-31 2009-07-02 Morinaga Milk Industry Co., Ltd. Interleukin production regulator, pharmaceutical composition or food comprising the interleukin production regulator, and method for production of the interleukin production regulator
US20080206213A1 (en) * 2007-02-28 2008-08-28 Bristol-Myers Squibb Company Method for reducing or preventing systemic inflammation
US9408819B2 (en) 2007-02-28 2016-08-09 Mead Johnson Nutrition Company Method for reducing or preventing systemic inflammation
US8767209B2 (en) 2010-06-02 2014-07-01 Beioptics Technology Co., Ltd. Broadband polarization spectrometer with inclined incidence and optical measurement system
CN111386124A (zh) * 2017-11-01 2020-07-07 表飞鸣制药株式会社 非甾体抗炎药及质子泵抑制剂所诱发的小肠损伤的预防或治疗剂
US11825856B2 (en) * 2018-03-28 2023-11-28 Morinaga Milk Industry Co., Ltd. Composition for preventing or improving functional gastrointestinal disorders, and, pharmaceutical composition, food/beverage composition, and method of preventing or improving functional gastrointestinal disorders using the composition for preventing or improving functional gastrointestinal disorders
WO2021021765A1 (en) * 2019-07-26 2021-02-04 Evolve Biosystems, Inc. Nutritive compositions with bioactive proteins
CN113943681A (zh) * 2020-11-12 2022-01-18 江南大学 一株降低炎症反应且具有缓解便秘作用的长双歧杆菌
WO2022103138A1 (ko) * 2020-11-13 2022-05-19 주식회사 비피도 비피도박테리움 롱검 rapo (kctc13773bp)를 포함하는 암 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
IL144185A (en) 2009-05-04
AU3071500A (en) 2000-08-01
HK1044964A1 (zh) 2002-11-08
AU3071600A (en) 2000-08-01
CN101744841A (zh) 2010-06-23
BR0007550A (pt) 2001-10-30
TR200102059T2 (tr) 2002-02-21
EP1145001B1 (en) 2006-05-10
NZ529353A (en) 2005-06-24
CN101744841B (zh) 2013-05-15
DE60027866D1 (de) 2006-06-14
WO2000042429A2 (en) 2000-07-20
US7195906B2 (en) 2007-03-27
RU2279282C2 (ru) 2006-07-10
US20050214272A1 (en) 2005-09-29
EP1143985B1 (en) 2007-07-25
EP1688481A1 (en) 2006-08-09
US20030170217A1 (en) 2003-09-11
ATE326012T1 (de) 2006-06-15
AU779405B2 (en) 2005-01-20
MXPA01007152A (es) 2003-04-02
TR200102058T2 (tr) 2001-12-21
NO20013429L (no) 2001-08-27
EP1141235A2 (en) 2001-10-10
BRPI0007481B1 (pt) 2015-12-15
US20030215467A1 (en) 2003-11-20
BRPI0007481A (pt) 2002-04-09
CN1338940A (zh) 2002-03-06
IE20000033A1 (en) 2000-08-09
US20060292133A1 (en) 2006-12-28
WO2000041707A3 (en) 2001-09-27
ID29150A (id) 2001-08-02
CN1245994C (zh) 2006-03-22
EP1143985A2 (en) 2001-10-17
RU2001119046A (ru) 2003-06-20
HK1044964B (zh) 2010-01-15
ATE367820T1 (de) 2007-08-15
BRPI0007481B8 (pt) 2021-07-06
CA2360243A1 (en) 2000-07-20
RU2308483C2 (ru) 2007-10-20
WO2000042168A3 (en) 2000-11-16
CN100552016C (zh) 2009-10-21
AU3071700A (en) 2000-08-01
DE60035670T2 (de) 2008-04-30
CA2359334A1 (en) 2000-07-20
NO20013467L (no) 2001-09-14
MXPA01007144A (es) 2002-04-24
DE60028003D1 (de) 2006-06-22
CA2724287A1 (en) 2000-07-20
CA2359334C (en) 2011-03-22
PT1141235E (pt) 2006-10-31
IL144184A0 (en) 2002-05-23
DK1141235T3 (da) 2006-09-18
EP1143985A3 (en) 2002-08-28
JP4706016B2 (ja) 2011-06-22
NO327792B1 (no) 2009-09-28
US20070141039A1 (en) 2007-06-21
JP2004502633A (ja) 2004-01-29
US20100112003A1 (en) 2010-05-06
NO20013467D0 (no) 2001-07-12
ES2265331T3 (es) 2007-02-16
ATE326525T1 (de) 2006-06-15
EP1145001A2 (en) 2001-10-17
EP1141235B1 (en) 2006-05-17
US20050074441A1 (en) 2005-04-07
JP2002534113A (ja) 2002-10-15
US20080311080A1 (en) 2008-12-18
US20080057109A1 (en) 2008-03-06
US20030166257A1 (en) 2003-09-04
CN1342196A (zh) 2002-03-27
WO2000041707A2 (en) 2000-07-20
US20050084482A1 (en) 2005-04-21
IL144185A0 (en) 2002-05-23
NO20013429D0 (no) 2001-07-10
ES2290008T3 (es) 2008-02-16
ID30449A (id) 2001-12-06
DK1143985T3 (da) 2007-11-19
DE60035670D1 (de) 2007-09-06
US20060002908A1 (en) 2006-01-05
DE60028003T2 (de) 2007-04-12
WO2000042429A3 (en) 2001-10-11
WO2000042168A2 (en) 2000-07-20
NZ530273A (en) 2005-04-29

Similar Documents

Publication Publication Date Title
CA2359334C (en) Bifidobacterium in the treatment of inflammatory disease
US20030092163A1 (en) Probiotic bifidobacterium strains
ZA200105617B (en) Bifidobacterium in the treatment of inflammatory disease.
IE20000034A1 (en) Bifidobacterium in the treatment of Inflammatory Disease

Legal Events

Date Code Title Description
AS Assignment

Owner name: ENTERPRISE IRELAND (TRADING AS BIORESEARCH IRELAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COLLINS, JOHN KEVIN;O'SULLIVAN, GERALD CHRISTOPHER;O'MAHONEY, LIAM;AND OTHERS;REEL/FRAME:011995/0047

Effective date: 20010625

Owner name: NATIONAL UNIVERSITY OF IRELAND, CORK, IRELAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COLLINS, JOHN KEVIN;O'SULLIVAN, GERALD CHRISTOPHER;O'MAHONEY, LIAM;AND OTHERS;REEL/FRAME:011995/0047

Effective date: 20010625

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION